Rapport Therapeutics (RAPP) Cash from Operations (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Cash from Operations of 13061000.0 for Q1 2026, up 35.46% year-over-year from 9641974.87 in Q1 2025, and up 47.12% quarter-over-quarter from 24701000.0 in Q4 2025.
Powered by 
Analysis
Rapport Therapeutics (RAPP) Cash from Operations (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Cash from Operations for 4 consecutive years, with 13061000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 35.46% year-over-year to 13061000.0; the TTM figure through Mar 2026 stood at 80297000.0 (down 19.05% YoY), while the FY2025 annual figure was 87473000.0, down 34.93% from the prior year.
- Cash from Operations advanced to 13061000.0 in Q1 2026 per RAPP's latest filing, from 24701000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 5424000.0 in Q3 2023 and bottomed at 25070000.0 in Q2 2025.
- Historically, Cash from Operations has averaged 16467545.45 across 4 years, with a median of 16415000.0 in 2024.
- Annual changes were most pronounced in 2024 — Cash from Operations sank 202.64% — and 2026, when it jumped 35.46%.
- Rapport Therapeutics' Cash from Operations stood at 10357000.0 in 2023, then tumbled by 39.48% to 14446000.0 in 2024, then sank by 70.99% to 24701000.0 in 2025, then surged by 47.12% to 13061000.0 in 2026.
- Business Quant data shows RAPP's Cash from Operations at 13061000.0 in Q1 2026, 24701000.0 in Q4 2025, and 17465000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Rapport Therapeutics | 2.17 Bn | 2.17 Bn | - | -41.46 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -41.46 Mn |
| Mar 31, 2026 | -13.06 Mn |
| Dec 31, 2025 | -24.70 Mn |
| Sep 30, 2025 | -17.47 Mn |
| Jun 30, 2025 | -25.07 Mn |
| Mar 31, 2025 | -20.24 Mn |
| Dec 31, 2024 | -14.45 Mn |
| Sep 30, 2024 | -16.42 Mn |
| Jun 30, 2024 | -16.35 Mn |
| Mar 31, 2024 | -17.62 Mn |
| Dec 31, 2023 | -10.36 Mn |
| Sep 30, 2023 | -5.42 Mn |